Abstract
Background and Aims
There are guidelines for the medical management of cirrhosis and associated quality indicators (QIs), but QIs focusing on standards for palliative aspects of care are needed.
Methods
We convened a 9-member, multidisciplinary expert panel and used RAND/UCLA modified Delphi methods to develop palliative care quality indicators for patients with cirrhosis. Experts were provided with a report based on a systematic review of the literature that contained evidence concerning the proposed candidate QIs. Panelists rated QIs prior to a planned meeting using a standard 9-point RAND appropriateness scale. These ratings guided discussion during a day-long phone conference meeting, and final ratings were then provided by panel members. Final QI scores were computed and QIs with a final median score of greater than or equal to 7, and no disagreement was included in the final set.
Results
Among 28 candidate QIs, the panel rated 19 as valid measures of quality care. These 19 quality indicators cover care related to information and care planning (13) and supportive care (6).
Conclusions
These QIs are evidence-based process measures of care that may be useful to improve the quality of palliative care. Research is needed to better understand the quality of palliative care provided to patients with cirrhosis.
Similar content being viewed by others
Abbreviations
- ESLD:
-
End-stage liver disease
- QI:
-
Quality indicator
- VA:
-
Veterans affairs
References
Walling AM, Asch SM, Lorenz KA, et al. The quality of care provided to hospitalized patients at the end of life. Arch Intern Med. 2010;170:1057–1063.
Teno JM, Gozalo PL, Bynum JP, et al. Change in end-of-life care for Medicare beneficiaries: site of death, place of care, and health care transitions in 2000 2005, and 2009. JAMA. 2013;309:470–477.
Meier DE. Increased access to palliative care and hospice services: opportunities to improve value in health care. Milbank Q. 2011;89:343–380.
Wachterman MW, Pilver C, Smith D, et al. Quality of end-of-life care provided to patients with different serious illnesses. JAMA Intern Med. 2016;176:1095–1102.
Kamal AH, Gradison M, Maguire JM, et al. Quality measures for palliative care in patients with cancer: a systematic review. J Oncol Pract. 2014;10:281–287.
Action Plan for Liver Disease Research: National Institute of Diabetes and Digestive Diseases and Kidney Disease http://www2.niddk.nih.gov/AboutNIDDK/ResearchAndPlanning/Liver_Disease/ActionPlanforLiverDiseaseResearchSlidesMinutes.htm. Last Accessed August 12, 2013.
UNOS Donate Life America Statistics. http://donatelife.net/understanding-donation/statistics/. Last Accessed December 30, 2014.
Larson AM, Curtis JR. Integrating palliative care for liver transplant candidates: “too well for transplant, too sick for life”. JAMA. 2006;295:2168–2175.
Roth K, Lynn J, Zhhong Z, et al. Dying with end stage liver disease with cirrhosis: Insights from SUPPORT. J Am Geriatr Soc. 2000;48:S122–S130.
Younossi ZM, Bopari N, Price L, et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol. 2001;96:2199–2205.
Kanwal F, Kramer J, Asch S, et al. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol. 2010;8:709–717.
The RAND/UCLA appropriateness method user’s manual. Santa Monica, CA, RAND Corporation, 2001.
Shekelle PG, Chassin MR, Park RE. Assessing the predictive validity of the RAND/UCLA appropriateness method criteria for performing carotid endarterectomy. Int J Technol Assess Health Care. 1998;14:707–727.
Zigmond DS, Ettner SL, Wilber KH, Wenger NS. Association of claims-based quality of care measures with outcomes among community-dwelling vulnerable elders. Med Care. 2011;49:553–559.
Higashi T, Shekelle PG, Adams JL, et al. Quality of Care is associated with survival in vulnerable older patients. Ann Intern Med. 2005;143:274–281.
Shekelle P. The appropriateness method. Medical Decision Making. 2004;24:228–231.
Kahn KL, Tisnado DM, Adams JL, et al. Does Ambulatory process of care predict health related quality of life outcomes for patients with chronic disease. Health Serv Res. 2007;42:63–83.
National Consensus Project for Quality Palliative Care. Clinical practice guidelines for quality palliative care. Executive summary. J Palliat Med. 2004;7:611–627.
National Quality Forum. NQF endorses palliative and end-of-life care measures. http://www.qualityforum.org/News_And_Resources/Press_Releases/2012/NQF_Endorses_Palliative_and_End-of-Life_Care_Measures.aspx. Accessed August 15, 2013.
Spengler U. Management of end-stage liver disease in HIV/hepatitis C virus co-infection. Curr Opin HIV AIDS. 2011;6:527–533.
Perumalswami PV, Schiano TD. The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci. 2011;56:1266–1281.
Hansen L, Sasaki A, Zucker B. End stage liver disease: challenges and practical implications. Nurs Clin North Am. 2010;45:411–426.
Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009;104:1802–1829.
Heidelbaugh JJ, Sherbondy M. Cirrhosis and chronic liver failure: part II. Complications and treatment. Am Fam Physician. 2006;74:767–776.
Soncini M, Leo P, Triossi O, et al. Management and outcomes of hepatic cirrhosis: Findings from the RING study. Hepatol Rs. 2006;36:176–181.
Sanchez W, Talwalkar JA. Palliative care for patients with end-stage liver disease ineligible for liver transplantation. Gastroenterol Clin North Am. 2006;55:201–219.
Lorenz KA, Rosenfeld K, Wenger NS. Quality indicators for palliative and end-of-live care in vulnerable elders. JAGS. 2007;55:S318–S326.
Lorenz KA, Dy SM, Naeim A, et al. Quality measures for supportive cancer care: The Cancer Quality-ASSIST Project. J Pain Symptom Manage. 2009;37:943–964.
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care in patients with metastatic non-small cell lung cancer. NEJM. 2010;363:733–742.
Higginson IJ, Finlay IG, Goodwin DM, et al. Is there evidence that palliative care teams alter end-of-life experiences of patients and their caregivers? J Pain Symptom Manag. 2003;25:150–168.
Bakitas M, Lyons Hegel MT, et al. Effects of palliative care intervention on clinical outcomes in patients with advanced cancer: the project ENABLE II randomized controlled trial. JAMA. 2009;302:741–749.
Walling AM, et al. Evidence-based recommendations for information and care planning in cancer care. J Clin Oncol. 2008;23:3896–3902.
Wright AA, Zhang AA, Huskamp H, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA. 2008;300:1665–1673.
Zimmermann C, Swami N, Krzyzanowskam M, et al. Early palliative care for patients with advanced cancer: a cluster-randomized controlled trial. Lancet. 2014;383:1721–1730.
Teno JM, Clarridge BR, Casey V, et al. Family perspectives on end-of-life care at the last place of care. JAMA. 2004;291:89–93.
Walling AM, Asch SM, Lorenz KA, Wenger NS. Impact of consideration of transplantation on end-of-life care for patients during a terminal hospitalization. Transplantation. 2013;95:641–646.
Acknowledgments
We acknowledge the significant contributions of the Palliative Care Cirrhosis Expert Panel including Bruce Bacon, MD, Sydney Dy, MD, MSc, Douglas Heuman, MD, Fasiha Kanwal, MD, MSHS, Timothy Morgan, MD, Teryl Nuckols, MD, MSHS, David Ross, MD, PhD, Tamar Taddei, MD, and Neil Wenger, MD, MPH. We appreciate the administrative support of Patricia Smith. We also appreciate the support of the VA HIV/Hepatitis QUERI and VA HSR&D (PPO 14-372). Dr. Walling was also supported by UCLA CTSI Grant Number UL1TR000124 and the NIH Loan Repayment Program.
Funding
This project was supported by the HIV/Hepatitis QUERI, Veterans Administration and VA HSR&D (PPO 14-372). Dr. Walling was also supported by NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number (UL1TR000124) and the NIH loan repayment program.
Author contributions
All authors were involved in the study concept and design and also in the data collection, analysis, and interpretation. AW, NW, and SA drafted the manuscript. All authors were involved in the critical revision of manuscript. AW, KL, and SA were involved in the study supervision. All authors were involved in the administrative, technical or material support. AW, MB, and SA were involved in the statistical analysis. AW, KL, and SA obtained the funding.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
For Drs Walling, Ahluwalia, Wenger, Booth, Dy and Asch there are no conflicts to disclose. Carol Roth has Johnson and Johnson stock. Dr. Lorenz is serving as a consultant to Otsuka Pharmaceuticals for data monitoring and safety in the evaluation of a Phase II trial of Sativex, a novel cannabinoid analgesic.
Appendix
Appendix
End-stage liver disease—search methodology
Database searched and time period covered:
PubMed—1990-3/22/2012
Language:
English
Search strategy;
End-stage liver disease OR (cirrhosis AND (child AND c))
AND
“dying loved one” OR “dying patient” OR “dying patients” OR “dying people” OR “dying person” OR “last year of life” OR “end of life” OR “end-of-life” OR “terminal illness” OR “terminal illnesses” OR terminal care OR “limited life expectancies” OR “limited life expectancy” OR “limited life span” OR “limited lifespan” OR “limited life spans” OR terminally ill OR critical illness OR frail elderly OR palliative OR hospice OR “advance care” OR advance directive* OR surrogate decision maker* OR surrogate decision-maker* OR caregiver* OR care giver* OR “care giving” OR diet* OR nutrition* OR supportive medication* OR hepatorenal syndrome AND dialysis) OR “mechanical ventilation” OR pain OR esophageal varices OR constipat* OR ascites OR bone OR bones OR fatigue OR pruritis OR gonadal dysfunction OR dyspnea OR tylenol OR nsaids OR sorafenib
Number of results: 1776
Database searched and time period covered:
PubMed—1/1/2012–12/14/2012
Language:
English
Search strategy:
End-stage liver disease OR (cirrhosis AND (child AND c))
AND
“dying loved one” OR “dying patient” OR “dying patients” OR “dying people” OR “dying person” OR “last year of life” OR “end of life” OR “end-of-life” OR “terminal illness” OR “terminal illnesses” OR terminal care OR “limited life expectancies” OR “limited life expectancy” OR “limited life span” OR “limited lifespan” OR “limited life spans” OR terminally ill OR critical illness OR frail elderly OR palliative OR palliat* OR hospice OR “advance care” OR advance directive* OR surrogate decision maker* OR surrogate decision-maker* OR caregiver* OR care giver* OR “care giving” OR diet OR dietary OR nutrition* OR supportive medication* OR (hepatorenal syndrome AND dialysis) OR “mechanical ventilation” OR pain OR esophageal varices OR constipat* OR ascites OR bone OR bones OR fatigue OR pruritis OR gonadal dysfunction OR dyspnea OR tylenol OR nsaids OR sorafenib
Number of results: 213
Database searched and time period covered:
Cochrane databases—1/1/2012–12/14/2012
Language:
English
Search strategy:
‘End-Stage Liver Disease OR (cirrhosis AND (child AND c)) in title abstract keywords
AND
dying loved one” OR dying patient OR dying patients” OR “dying people OR dying person OR last year of life OR end of life OR end-of-life OR terminal illness OR terminal illnesses OR terminal care OR limited life expectancies OR limited life expectancy OR limited life span OR limited lifespan OR limited life spans OR terminally ill OR critical illness OR frail elderly OR palliative OR palliat* OR hospice OR advance care OR advance directive* OR surrogate decision maker* OR surrogate decision-maker* OR caregiver* OR care giver* OR care giving OR diet OR dietary OR nutrition* OR supportive medication* OR (hepatorenal syndrome AND dialysis) OR mechanical ventilation OR pain OR esophageal varices OR constipat* OR ascites OR bone OR bones OR fatigue OR pruritis OR gonadal dysfunction OR dyspnea OR tylenol OR nsaids OR sorafenib
Number of results: 2
Cochrane reviews (2)
Other reviews (0)
Trials (2)
Methods studies (0)
Technology assessments (0)
Economic evaluations (0)
Cochrane groups (0)
After removing duplicates:
1888 is the final after removing all duplicates
144 after title search
82 after abstract search
Database searched and time period covered:
National guidelines clearinghouse—1/1/1997–12/14/2012
Language:
English
Search strategy #1:
Keyword: liver
IOM care need: end-of-life care
Number of results: 41
Search strategy #2:
Keyword: cirrhosis
Age of target population: exclude infant (1–23 months), child (2–12 years), adolescent (13–18 years)
Number of results: 38
No Palliative care guidelines for cirrhosis, General Palliative care guidelines for pain management (1) and for all life-limiting illnesses (2)
Database searched and time period covered:
CareSearch—all years
Search strategy:
Liver
Number of results: 25
One report for homeless, one report for pain management in liver disease, and fast fact #189 for prognosis in cirrhosis
Rights and permissions
About this article
Cite this article
Walling, A.M., Ahluwalia, S.C., Wenger, N.S. et al. Palliative Care Quality Indicators for Patients with End-Stage Liver Disease Due to Cirrhosis. Dig Dis Sci 62, 84–92 (2017). https://doi.org/10.1007/s10620-016-4339-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-016-4339-3